Effect of Lipid Lowering Agents on Diabetic Retinopathy and Cardiovascular Risk of Diabetic Patients
NCT ID: NCT04140201
Last Updated: 2020-01-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
80 participants
INTERVENTIONAL
2020-02-29
2020-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of CNV With Aflibercept Combined With Pranoprofen Eye Drops or Nutraceutical Support With Omega-3
NCT03355638
A Study of the Effect of Different Doses of Difluprednate Eye Drops on the Intraocular Pressure After Phacoemulsification
NCT05649111
NSAID Phase II for Non-central Involved Diabetic Macular Edema (DME)
NCT01331005
IVI Aflibercept Before and After Phaco in DME.
NCT05731089
Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-003)
NCT00616070
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Receive oral hypoglycemic +omega 3
Eicosapentanoic acid + standard treatment
Omega 3 fatty acid
Drugs that lower lipid levels
Receive oral hypoglycemic +statin
Simvastatin + standard treatment
Simvastatin 40mg
Drugs that lower lipid level
Receive oral hypoglycemic +fibrate
Fenofibrate +standard treatment
Fenofibrate 200mg
Drugs that lower lipid levels
Receive oral hypoglycemic only
Standard treatment only
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Simvastatin 40mg
Drugs that lower lipid level
Fenofibrate 200mg
Drugs that lower lipid levels
Omega 3 fatty acid
Drugs that lower lipid levels
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Non proliferative diabetic retinopathy
Exclusion Criteria
* proliferative diabetic retinopathy
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alaa Hassan ElBaz
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alaa Hassan ElBaz
Assistant lecturer at beni suef university
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Diabetic Retinopathy
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.